SDICVC sets focus on advanced manufacturing, electronic information TMT, energy, environmental protection, biomedicine and other fields. The projects invested in have been regarded by the concerned industries and society, and achieved good effects of policy and extensive social impact.
In December 2017, SDIC Venture Capital finished its strategic investment in Shenzhen Nanolighting Lab Ltd. (hereinafter referred to as Shenzhen Nanolighting) with its National Science and Technology Fund so as to support the enterprise further strengthening and reinforcing its technical leadership in the field of optic inspection in China and catching up with the world-leading technical level.
Shenzhen Nanolighting is the commitment unit of our National Key Research and Development Plan of “Exterior membrane structure three-dimensional optical tester”, as well as a leading enterprise which has developed its own advanced packaging and test equipment, three-dimensional optical measuring module and overall equipment and realized massive shipment. Now, the products of Shenzhen Nanolighting mainly cover the fields of semiconductor and 3D glass. The optic wafer test equipment used in semiconductor industry has developed Cypress, the three-dimensional topography measurement equipment and Spruce, the surface inspection equipment and Birch, the intelligent visual inspection system. Its products have been in stable operation for many years in various domestically leading wafer production and packaging manufacturers. Totora, the precise inspection system for 3D glass, has solved the problem of inefficient inspection of 3D glass and enters into cooperation with many renowned domestic manufacturers producing consumer electronics glass.
The strategic investment of National Science and Technology Fund in Shenzhen Nanolighting will help the company continuously increase its input in R&D, improve its technical strength rapidly and reduce the dependence of domestic wafer manufacturers and packaging manufacturers on competing products. The rapid development of Shenzhen Nanolighting will hopefully further improve domestic integrated circuit industry chain. While improving the overall technical level of its own industry, it will also cultivate professionals with independent research and development skills in the field of optic inspection equipment.
In December 2017, SDIC Venture Capital finished its strategic investment in Shandong Digihuman Technology Co., Inc. (hereinafter referred to as Digihuman) with its Hi-tech Venture Capital Fund. Digihuman has been supported by provincial science and technology major projects twice. It is in the leading position in the subdivided fields like medical anatomy education and medical morphology education. Its software and hardware system for digital anatomy teaching can effectively alleviate the problem of insufficient dissections and tissues in basic anatomy education and represents the trend of medical education in the future.
By cooperating with Army Medical University, the commitment unit of “China Digital Human Project” included in 863 Program, Digihuman managed to develop the first domestic digital anatomy teaching system based on real cross-sectional anatomy data. According to Chinese Society for Anatomical Sciences, this system has reached the international advanced level and fills the domestic gap. Meanwhile, more detailed data on the structure of human body will hopefully enter the filed of digital health.
In November 2017, SDIC Venture Capital accomplished its investment in Hangzhou Li-On Microelectronics Co., Ltd (hereinafter referred to as Li-On Microelectronics).
Li-On Microelectronics gives its priority to automotive electronic chips, power management IC chip and large silicon wafer for integrated circuit and also pays attention to the strategic layout of the 6-inch, second-generation semiconductor microwave radio frequency integrated circuit chips. Li-On Microelectronics has developed into a leading enterprise in the subdivided industries of power semiconductor in China as well as the largest provider and exporter of power Schottky chip. In June 2015, it took full control of Jinruihong Technologies Co., Ltd, the largest manufacturer of semiconductor silicon wafer in China, becoming the only domestic industrial platform that is capable of manufacturing monocrystalline silicon, grinding silicon wafer, polished silicon wafer, epitaxial silicon wafer and chip. In July 2015, Li-On Microelectronics introduced overseas high-level talents and established the only production line of 6-inch GaAs RFIC chip in China, making up for the gap of core technology in radio frequency integrated circuit industry and meeting the demands for booming industries like wireless communications.
Hi-tech Venture Capital Fund will help to improve the capacity of MOSFET, accelerate the construction of the production line of GaAs RFIC chip, effectively reduce China’s dependence on foreign products of the same kind, so that it will hopefully contribute to the further development of domestic semiconductor industry.
In December 2017, SDIC Venture Capital accomplished its strategic investment in Ningbo Jiang Chen Automation Equipment Co., Ltd. (hereinafter referred to as Jiang Chen) with its High-Tech Venture Capital Fund to overall support Jiang Chen becoming the leading enterprise in the field of automotive automatic assembly line equipment in China and accelerating the process of replacing foreign products with domestic ones in automotive equipment industry.
As a NEEQ-listed company, Jiang Chen mainly focuses on R&D, manufacturing, integration and integrated solution of automatic assembly lines of automotive powertrain, bearing, new energy vehicle batteries and so on. It is the commitment unit included in the National Torch Program and identified as an industrialization demonstration project. Its clients include many renowned automobile and key components manufacturers, such as Geely Auto, Wanliyang, Corun, Dongfeng Honda and NIO. Furthermore, Jiang Chen received strategic investment from Geely Auto and ASD (Zhejiang) in 2017, and other related enterprises will continue to deepen their financial cooperation, business support and resource integration so as to accelerate development collaboratively.
With the strategic investment from Hi-tech Venture Capital Fund, Jiang Chen, relying on its own abundant technical strength, will provide efficient, intelligent automation equipment for clients with all-around and high-level capability, further expand its influence in the industry, reduce the dependence of automotive equipment industry on foreign manufacturers, accelerate the process of replacing foreign products with domestic ones and contribute to the realization of “advanced manufacturing”, “smart factory” and “industry 4.0”.
In October 2017, SDIC Venture Capital invested in Chipone Technology (Beijing) Co, Ltd. (hereinafter referred to as Chipone Technology) with its National Science and Technology Fund to support Chipone Technology further consolidating and strengthening its technical leadership in the field of panel display ICs. This round of funding will be mainly used to further increase R&D investment in the next generation of panel display technology.
Chipone Technology is the commitment unit of “Domestically designed LCD, verification and industrialization of Gold Bump” project, one of National Major Scientific and Technological Special Project, and the world's leading display-control- chip overall solutions provider. It’s equipped with kernel technologies of the display panel ICs, independent intellectual property rights and the whole product line layout. Its clients cover all the major panel manufacturers in the world, including BOE, CSOT, Panda, Samsung, LG, Sharp, AUO, Innolux and so on. With years of accumulation of technology, Chipone Technology has now formed three major product lines: power management chip and driver chip for both medium and large LCDs; driver chip, touch control chip, fingerprint identification chip, power management chip and ITD chip for small LCDs; and display driving chip for large LEDs. In 2016, Chipone Technology successfully acquired IML, a world-leading company in the field of power management IC design whose main products are programmable gamma correction circuit buffer chip/common driver chip, power management chip, LED lighting chip, etc. Its P-GAMMA and VCOM products are in the leading position in the industry.
The strategic investment of National Science and Technology Fund will help Chipone Technology catch the historical opportunity of the rise of domestic panels and smart terminal industry, as well as the opportunity of industry change, further increase the R&D investment into ITD, Ultra-HD driver IC for large panels and OLED driver IC, strive to fill gaps of high-end chips in China’s panel and IC industries, and overtake the foreign competitors.
In December 2017, SDIC Ventures Capital invested in Shenyang Fortune Precision Equipment Co. Ltd. (hereinafter referred to as Fortune Precision) with National Science and Technology Fund to support Fortune Precision to further expand the supply of precision components and parts of China-made integrated circuit and equipment. This investment is of great significance to make up for the weak link in the industrial chain and create a complete domestic semiconductor industrial chain.
Fortune Precision is a unit undertaking a number of major national science and technology projects such as "Ultra-Large Scale Integrated Circuit Manufacturing Technology and Whole Set of Processes" and is also a national precision parts supplier that has independent intellectual property rights and is continuously supported by the state in the field of precision components.
Fortune Precision is devoted to the integrated circuit equipment and aviation areas, from parts, providing the services of components and sub-system components machining, surface treatment, welding, etc. The company has become the leading precision parts manufacturing and system solution provider in China. In the area of integrated circuits, the company, as a national IC equipment industry component manufacturing platform, has successfully provided supporting services to domestic IC equipment leaders such as Shanghai Micro Electronics Equipment (Group) Co., Ltd., Beijing North Microelectronics Co., Ltd., and VeriSilicon Holdings Co.,Ltd., providing producing and processing services to more than 150 IC companies. In the field of aviation, the company has become the civilian aircraft supplier of AVIC Shenyang Group, undertaking the precision parts manufacturing tasks for the C919 and other types of aircraft.
In October, 2017, SDIC Venture Capital Co., Ltd. has completed the investment in Zhejiang Jinruihong Technologies Co.,ltd.(hereafter referred to as JRH) with its National Science and Technology Fund. With the fund, JRH Electronics will be able to continue its research and development on high-end semiconductor materials, improve its productivity to boost the spirit of the company, fasten the process of replacing foreign semiconductor materials with domestic ones, and provide a strong support for the implementation of the strategy for national integrated circuit development as well as the domestic transfer of the semiconductor industry.
The supply of reliable and high quality upstream materials is of great importance to the development of the semiconductor industry and even to the information industry.
Silicon wafer is the core basic material to produce integrated circuits and discrete devices. However, China's large-size silicon wafer has always been largely dependent on imports, thus the competitiveness and supply chain security of our country has been severely restricted. JRH has an outstanding capacity in the research & development and industrialization of silicon wafer technology. JRH is the only the semiconductor company in China that has the full range of capability on single crystal silicon, grinded wafer, polished wafer, epiwafer and discrete device production, and has broken the monopoly of foreign companies on semiconductor silicon wafer of 8 inches, thus contributing greatly to narrowing the development gap between China and the world. JRH could produce about 8 million silicon wafers every year, and has become the biggest manufacturing base in China. With its stable products, JRH extends its market to the world, doing business with many renowned wafer manufacturers in countries and regions such as the US, South Korea and China Taipei, and with some related domestic enterprise such as Semiconductor Manufacturing International Corporation and Shanghai Huahong (Group) Co., Ltd.
In August, 2017, the National Science and Technology Fund of SDIC Venture Capital, the National Integrated Circuit Industry Fund and the CRRC Investment&Leasing Co., Ltd have together completed the investment in Shenyang Piotech Co., Ltd., (hereafter referred to as Piotech). The investment will help Piotech become one of the leading IC equipment companies in China and increase its speed entering the international market, making it a domestic semiconductor manufacturing company with world-class products.
Piotech has undertaken significant projects on integrated circuit granted by the “National Science and Technology Project”, and has become the leading supplier in China with proprietary intellectual property to produce integrated circuit thin film equipment used in production lines. The company is focused on the research, development and production of PECVD equipment, with overseas experts and domestic talents including 3 experts selected into China’s Thousand Talents Program and operates under international industry standards. The products of Piotech have already entered industrial stage. With its market scale expanding rapidly, the company is now doing business with some high-end customers such as Semiconductor Manufacturing International Corporation(SMIC), Yangtze Memory Technologies Co., Ltd and Xiamen Lianxin Integrated Circuit Manufacturing Corporation. In December, 2017, its number of thin film equipment in SMIC’s commercial product lines has been over 1 million, and all indicators of the equipment have reached advanced international level. With the semiconductor manufacturing industry in China booming as a whole, there will be huge market demand on domestically-made integrated circuit thin film equipment with the value totaling over 30 billion RMB.
ZSHIELD was founded by numerous senior technical elites in network data security from Silicon Valley. It is the first high-tech company in China specializing in cyberspace data security and risk management and control of big data services based on big data technologies of ‘perception’ ‘detection’ and ‘behavior’.
The ZS-ISP intelligent security platform proposed by ZSHIELD is an international leading data security working platform and management & control system based on lightweight virtualization, deep learning and big data analysis; the ZS-HIAP holographic auditing platform is an international leading business analysis and auditing system based on distributed computing, machine learning, sensor technology, big data storage and analysis; the ZS-ISA intelligent security probe system is a high-efficiency server and terminal monitoring and management tool.
ZSHIELD provides multiple solutions for the government, finance, electric power and high-tech industries, which are now widely applied to key administrative departments and electric power, IC design, banking and insurance fields.
ENMO Tech focuses on IT infrastructure library and data services, encourages the productization of IT services and the intelligentization of operation and maintenance, and provides integrated solutions of database services for many clients. Thanks to its businesses including consulting service of architecture, performance improvement, integration and migration, and monitoring and operation & maintenance, ENMO Tech has always been an industry leader in this market. Through strengthening user data security, improving user experience, decreasing the cost of IT operation & maintenance, ENMO Tech focuses on clients’ data assets, offering high-value solutions, supportive software and professional services revolving around business structure, data architecture, application architecture and IT infrastructure, thus to help clients to build and support a secure, constant, efficient and economical data environment and dig out great value hidden in data.
With a top-ranking team of experts, ENMO Tech has been acknowledged by almost 300 clients from key industries in 6 years and its business pattern has been tested by practice, gaining nice public praise.
SKYGUARD is an information security enterprise oriented by the advanced content security technology with the mission of independent controlled security, and has constructed the largest R&D team based on content security in China. Focusing on growing new needs of enterprises for data security protection, staying in line with the regulations of Cybersecurity Law of the People's Republic of China, SKYGUARD deeply analyzes the characteristics of our users’ practical use, customizes comprehensive solutions for enterprises’ data security covering network, terminals and cloud environment and helps users to effectively avoid data breaches and protect the security of key data assets.
In 2017, SKYGUARD’s ITM solution based on behavior analysis and the ITP system exclusively realized intelligent fusion of content-based security engine and user-behavior-analyzing engine worldwide, leading the trend of new data security technology.
Founded in January 2012, Suzhou INVO Automotive Electronics Co.,LTD is committed to the R&D and sales of advanced driver assistance system (ADAS). Based on self-developed camera sensors, it has realized the bulk sales of panoramic display system and lane departure warning system (LDW) and so on, and become the leading company in domestic ADAS field.
Relying on the accumulated IDAS technology from automotive engineering department of Tsinghua University, Suzhou INVO has developed panoramic display with camera as sensor, lane departure warning and forward collision warning (FCW) solution answering industrial demand. The main customers include Guangzhou Automobile Group , Chang'an, Geely, Zotye, Dongfeng Nissan, Yutong Bus and King Long, and other famous passenger car and commercial vehicle manufacturers.
Songheng Network Technology Co., Ltd. (hereinafter referred to as Songheng Network) is a high-tech enterprise focusing on the design, R&D, operation and promotion of mobile Internet products subordinated to eastday.com. Its AI research institute boasts over 200 research staff and cooperates with Shanghai Jiaotong University on cutting-edge technologies including NLP, image recognition and big data analysis.
Based on technologies from independent research and development, Songheng Network improves the quality and efficiency of services and products effectively taking practical scenarios into consideration. The new-type news aggregation mobile new media mini.eastday.com served by Songheng Network effectively combining individualized recommended information with multiple needs of users, transcends the limit of traditional news media and provides professional services for clients through targeted advertisement marketing and other traffic monetization patterns, thus to scale apply technologies and products.
Hangzhou Jimu Technology Co., Ltd. (hereinafter referred to as Jimu Tech) is an innovative high-tech company specializing in artificial intelligence and key technologies of robots. The company is devoted to the R&D of autonomous driving technology and intelligent control technique and their applications in the fields of wheeled robots. Established in July 2016, Jimu Tech boasts a R&D team with rich industry experience and cutting-edge technical skills, whose key members are the top technical elites from Lenovo, Intel, CMU Robotics Institute etc., covering artificial intelligence, vehicle design, smart device, robots areas. Based on smart autonomous driving technology, Jimu Tech focuses on industrial wheeled robot, which can be widely applied to parking lots, storage and logistics. The first product of Jimu Tech is the parking robot with mechanical gripper, which is based on autonomous driving technology and has completed its design from mechanical structure, electronic engineering, software to algorithm. It is expected to make a test run and begin mass production in 2018.
HYDATA is the leading company which focuses on the application of AI = and visual analysis to the big data field in China. Specializing in the AI and visual analysis technology and relying on computer graphics and data analysis algorithms, HYDATA explores the hidden commercial value of big data, endows users with smart decision-making capacity and helps users to improve efficiency and monetization in business scenarios.
HYDATA offers comprehensive enterprise-class operating and analyzing services of big data. Its major product is the TUEASY big data analysis platform, covering public security, intelligent transportation, military and civilian integration, smart city, intelligent business management, providing integrated big data analysis services. Its services and products have been applied and acknowledged by strategic clients from the public security and aviation industries. HYDATA was named one of Cool Vendors 2017 by Gartner. It is a big data application company with proprietary technology.
Gu’an Higo Automobile Technology Co.,Ltd (hereinafter referred to as Higo Automobile) is a newly-rising enterprise of intelligent connected vehicles, engaging in the R&D and promotion of intelligent drive system. Established in 2017, Higo Automobile is derived from the State Key Laboratory of Automotive Simulation and Control, College of Automotive Engineering, Jilin University, whose key technical team has been working in driver simulation and advanced chassis system for more than 20 years and used to undertake over 10 national and provincial projects including National Key Research and Development Program of Ministry of Science and Technology, Key Project of National Natural Science Foundation, and Key Project of Automobile Development of the 863 Program; and has engaged in dozens of enterprise projects of original equipment manufacturers (OEM) and suppliers, acquiring rich scientific achievements and industry experience.
As an entrepreneurship pioneer of College of Automotive Engineering of Jilin University in the field of intelligent connected vehicles, relying on profound technology accumulation, broad vision and rich industry resources, Higo Automobile has built close partnerships with numerous domestic auto factories covering FAW, Dongfeng Motor Corporation, Chang’an Automobile, Chery Automobile, Guangzhou Automobile and Beijing Automotive Group.
In June 2017, SDIC Venture Capital completed the investing process in 360 Enterprise Security Group (hereinafter referred to as 360 Group) via its National Science and Technology Fund and other social capital driven by the dedicated fund. This investment project of 360 Group will greatly promote the achievement application of major national science and technology projects to the cyberspace security, and effectively support the growth of the enterprise into a leading enterprise in information security industry in China, as well maximize its influence in the world and jointly build a national information security moat.
360 Enterprise Security Group, the leading enterprise in China's cyber security industry, is committed to providing new generation network security products and services to government and enterprises. Its predecessor, Beijing Qihoo Technology Co., Ltd., has received more than 100 million yuan of scientific research funding including the National Science and Technology Major Project entitled "The New Generation Broadband Wireless Mobile Communication Network". Its major products and services include cloud security detection for websites and cloud service platforms, cloud security prevention technology and the "Wang Shen" intrusion prevention system, which all represent the most advanced technology development direction in the Internet era. 360 Group is the important leader and participant in the cyber security industry in China and even in the world.
Bangsun Technology is a provider of big data analysis supporting technology with complete intellectual property rights, and a leader of international real-time financial risk control & anti-fraud and big data applications. Established in 2010, it constructed an international leading technical team led by Academician Chen Chun of Zhejiang University and its ‘Real-Time Stream Big Data Analysis Technology and Platform’ won the First Prize of Scientific and Technological Progress of Ministry of Education of China.
Software products including real-time risk control, real-time credit extension, and real-time anti-crawler developed by Bangsun Technology based on real-time big data processing platform, Stream Cube, boast strong real-time processing ability, enjoying high application value in anti-fraud, anti-cheat, anti-crawler, anti-scalper, liquidity risk monitoring, small credit extension, targeted marketing, real-time criminal investigation, real-time decision-making and so on, acknowledged by numerous iconic clients. It has successfully been serving to hundreds of banks, securities traders, third-party payments, online finance, and boasts international leading major performance index. Meanwhile, the strong real-time processing ability of Stream Cube can fairly satisfy the needs of industries with great business flow and high concurrency and time-sensitive requirements, which can be widely applied to non-financial fields including aerospace, energy and power, rail transportation and military industry & anti-terrorism.
The Twenty First Century Aerospace Technology Co. Ltd (hereinafter referred to as 21AT) was the first service provider of commercial remote sensing satellite operation and application in China, boasting the Beijing-1 and Beijing-2 small satellites and other branded applications well known at home and abroad. Established in 2001, with the tenet of ‘Act the leading role in professional domain; Attach importance to convergence’, the 21AT has developed multiple capabilities in applications of remote sensing satellites including scale production and processing, customized application software development, multi-technology fusion, large system integration and professional application services. It also initiated a long-term mechanism of regional governmental services, offering comprehensive solutions of integrated remote sensing information application for land resources management, ecological environment monitoring, resources investigation and statistics, sophisticated urban planning, and emergency response for disasters. The 21AT is now a leading enterprise in the industry of remote sensing satellite applications.
The 21AT sticks to independent research and development and closely cooperates with famous academies and R&D institutions in China. It has undertaken and successfully completed numerous major projects covering the 863 Program, Key Research Project of Ministry of Science and Technology and Special Industrialization Project of NDRC. Furthermore, its achievements have been repeatedly awarded by national and provincial scientific awards like the Gold Award of GIS, the Science & Technology Award of Land Resources Management, and Beijing Science and Technology Award; and it has acquired hundreds of proprietary intellectual property rights of key technologies.
In August 2017, SDIC Venture Capital, as the lead investor joined by Ali, Lenovo, Guo Ke Rui Hua and other well-known investors, established the National Science and Technology Fund and completed its investment in Beijing Zhongke Cambricon Technologies Co., Ltd. (hereinafter referred to as "Cambricon"). Cambricon has become the world's first AI chip unicorn companies. More social capital investment driven by SDICVC's National Science and Technology Fund will hopefully promote Cambricon to become a leading AI company on a par with other international giants, build a new generation "China Chip" to promote the industrialization of China's artificial intelligence and other cutting-edge scientific and technological achievements.
Emerged from the Institute of Computing Technology, Chinese Academy of Sciences, Cambricon is a high-tech company committed to the development of deep-learning-based ASIC. Cambricon aims to provide artificial intelligence acceleration chips for all kinds of servers, intelligent terminals and intelligent robots. Its products solve the pain points of large-scale data processing capability of artificial intelligence chips and will be applied to all kinds of intelligent terminals and servers in large scale. It is an important underlying support for Artificial intelligence technology. Cambricon has established a good cooperation with other leading enterprises upstream and downstream, and been broadly acknowledged by other companies, like Ali, Huawei, Sugon, etc.
Cambricon has two product lines to produce AI terminal processor IP and cloud high-performance AI chip. Released in 2016, the Cambricon-1A processor is the world's first commercially available deep learning processor targeted at a wide range of end devices such as smartphones, security surveillance, drones, wearable devices and smart driving. When running the mainstream smart algorithm, its performance per watt exceeds the traditional processor in all aspects. It is also selected as the "world leading Internet scientific and technological achievements" in The Third World Internet Conference in Wuzhen among other 15 outstanding products at home and abroad, including Ali’s Apsara Platform, Sunway TaihuLight, Huawei Kirin 960, Tesla, Microsoft HoloLens, IBM Watson. The company’s achievements have been widely reported by CCTV News, People's Daily, Xinhua News Agency, CNN, MIT Technology Review and other domestic and foreign mainstream media. Currently, Cambricon terminal processor IP products have derived 1A, 1H and other models. In the next few years, hundreds of millions of terminal devices worldwide are expected to be integrated by the Cambricon processor to obtain a strong local smart processing capability.
QUADAS is the service provider of mobile marketing SaaS for advertisers, agents, traffic and other ecological parties, providing fast access to data and technology capabilities.
Established in September 2011, Quadas used to be the original advertising technical services division of Vpon Ads Company, and completed the spin-off from Vapon in 2016. The technologically innovative SaaS model of Quadas could meet the interests of advertisers, agents and flow parties through technical approach, serving the entire digital ecosystem to the best and cutting into the great market space. The company's platform architecture has undergone the test of a large number of traffic delivered by Vpon, accumulated huge mobile marketing data during the past 8 years, and finally obtained its core technology and data service capability. The major clients of Quadas include Cheetah Mobile, Allyes Ads, Viscovery, OMP, iProspect, Guangzhou Daily, Xiangxieli Advertising Media, Granville, Vpon and other traffic agents.
Changzhou ECTEK Automotive Electronic System Co.,Ltd. (hereinafter referred to as ECTEK) is a high-tech enterprise focusing on the R&D and production of automotive electronic control technologies. Established in 2005, originated from a startup project of Tsinghua University, the company maintains close contact with well-known academies like Tsinghua University and Jiangsu University in technological innovation, talent training and scientific research and development. There has already set up a cooperative pattern where ECTEK acts as a platform for industry-university-research transformation and academies provides technical support. ECTEK always leads the technology of power system and emission control, and masters key technologies through independent research and development. Moreover, it has completed the R&D and industrialization of product series including engine controller, dual-fuel engine, controller system and SCR system controller that satisfy National Level 4 emission standard; the vehicle controller for electric vehicles manufactured by ECTEK is capable for bulk supply. Meanwhile, ECTEK has undertaken numerous research tasks for international scientific cooperative and supporting projects as well as National Innovation Fund projects. ECTEK now boasts 19 national patents and 27 software copyrights.
In virtue of its profound technology accumulation and industrialization experience for years, ECTEK has built good partnerships with major domestic fuel injection equipment factories, engine factories and original equipment manufacturers (OEM), whose products have been acknowledged and widely applied in many OEMs including FAW, Dongfeng Motor Corporation, Shaanxi Automobile Group, Fukuda, and CSR Corporation Limited. ECTEK is also a major supplier of control system products in ship, motor, engineering machinery and other special-type power industries.
YOYOSYS is committed to the R&D of big data and cloud computing technology, developing CloudWare series big-data software with complete intellectual property rights. Based on this technology, the company forms the comprehensive solution suitable for many industries, covering data storage/access, data computing/analysis, and system operation & maintenance management, which makes the company becoming the leading supplier of cloud computing and big data technology.
Revolving around the product development idea of ‘independent and controlled key technology; open and inclusive architecture’, YOYOSYS has developed three big data processing products including YOYOSYS data flow control system, Yiyun data exchange platform and Yiyun big data platform, which are acknowledged as national key innovative products. The cloud computing and big data products independently developed by YOYOSYS are applied to the government, transportation, electric power and telecom industries, as well as undertake related tasks of Earth Observation and Navigation, offering great support for National Science and Technology Major Project.
In September 2016, SDIC Ventures completed its investment into Zhongding Dairy Farming Co., Ltd. (hereinafter referred to as Zhongding) with the High-tech Venture Capital Fund. Zhongding Dairy Farming is a joint-stock enterprise engaging in dairy farming and animal husbandry management. Since its establishment in May 2013, Zhongding has integrated nearly 100 pastures in China and signed 60,000 dairy cattle, making it the largest innovative dairy farmers cooperatives in China. In view of the existing pasture, Zhongding carries out the "integration of stock", outputs technology and management, and optimizes the allocation of resources. From raw material procurement, dairy farming, to the raw milk sales and management, Zhongding lays the integration platform of the industrial chain through the innovative way of "full custody".
In 2017, China-Israel Dairy Cooperation Program landed in Zhongding Dairy Farming. The China-Israel Dairy Technology Cooperation Industrial Park will be operated and managed by Zhongding. The company is devoted to integrating the upstream and downstream enterprises in the dairy industry chain with "stock+increment" and building a national demonstration project in which both countries will exchange international advanced technologies. As China-Israel Dairy Cooperation Program planed, in the next three years (2018-2020), China will introduce Israeli dairy industry production technology, management and social service system to create an international husbandry demonstration zone with 40,000 cow. Meanwhile, the two parts will construct China-Israel Dairy Technical Cooperation Service Center and TMR distribution center, integrated manure processing and organic fertilizer production center, overseas research and exchange center, cheese processing factory, start-up incubator and other construction project, and finally establish the China-Israel Dairy Technology Cooperation Industrial Park.
As a livestock management and technology export platform, Zhongding will contribute to the supply-side structural reform of China's upstream dairy industry.
In December 2017, the Beijing-Tianjin-Hebei Fund managed by SDIC Venture Capital successfully completed the investment in Beijing Honghui International Energy Technology Development Co., Ltd. (hereinafter referred to as Honghui Energy). Honghui Energy is China's best flywheel energy storage technology provider with independent intellectual property right. The Honghui Energy investment project from Beijing-Tianjin-Hebei Fund is not only a concrete measure to implement the coordinated development strategy of Beijing, Tianjin and Hebei and accelerate commercialization of research findings in Beijing, Tianjin and Hebei, but also a typical case to respond and promote the strategy of military and civilian integration.
Honghui Energy is a high-tech enterprise that integrates military and civilian, and applies space technology into civilian use. It brings together top experts in Aerospace, Power Electronics, Automatic Control and Energy in China, and has developed a series of cutting-edge, fully independent intellectual property-based flywheel energy storage technology and products. Honghui Energy's flywheel energy storage technology successfully broke the technical blockade long-established by the developed countries, which increases stabilization of the satellite attitude by 1-2 orders of magnitude and has a very important strategic significance to national defense.
On this basis, Honghui Energy has developed a flywheel energy storage product designed for industrial application. The product can be widely used in millisecond-level uninterruptible power supply for large data centers, telecommunications, integrated circuits and other high precision manufacturing. At the same time, flywheel batteries are expected to be applied to rail transit braking energy recovery, power's peak-load regulation, microgrid, civil air-defense projects, wind and solar energy storage, and other areas in large scale owing to its characters of eco-friendliness, efficient energy recovery, uninterrupted and long-life power supply and so on.
In April 2017, SDIC Venture Capital, joined by CDH Investments and other VC institutions, completed the investment in Microvast Power System (Huzhou) Co., Ltd. (hereinafter referred to as Microvast) with its National Science and Technology Fund. The SDICVC's major special funds involved in this investment plays a leading role to attract more investment, and help Microvast to innovate the technology, to promote its materials, to further expand production capacity, to consolidate the resources of the industrial chain, and to keep its leading position in technology as well.
One of the bottlenecks in the development of electric vehicles lies in the power battery. Battery performance is also one of issues concerned most by the users. As one of the few solution providers of vertically integrated electric vehicle power system, Microvast is fully considering user's need and proud to offer its innovative "fast-charge, long-life, non-burnable" lithium-ion battery. The product is taking the leading position both in technology and in the market coverage, and well received by the international well-known vehicle companies. With more than 6 years of commercial operation progressively carried out in more than 140 cities in 6 countries around the world, Microvast successfully injected the concept of "fast-charge" into the electric vehicle industry. Especially in the field of public transport, it has also set a milestone in operations including cities such as Chongqing, Beijing and London, and has gained user's extensive acceptance. Currently, there are 288 bus companies in China that have applied Microvast's solution.
In December 2017, National Science and Technology Fund managed by SDIC successfully worked with the State-owned Key Enterprises Poverty Regional Industrial Investment Fund to invest in Shenzhen Zhenhua E-CHEM Co., Ltd (hereinafter referred to as Zhenhua E-CHEM or the corporation). The fund will finance the construction of the new plant of Zhenhua E-CHEM in the poverty-stricken area in Guizhou. Owning to this round of investment, Zhenhua E-CHEM will acquire more resources for strategic development, leading the technological development of anode material for Lithium battery and gradually developing into a leading enterprise in its industry.
Anode material is the core material which determines the overall energy density of the Lithium battery. Zhenhua E-CHEM is a subordinate corporation of China Zhenhua Electronics Group Co., Ltd as well as a NEEQ-listed company. 12 years have passed since the company took up the research and development of anode material for Lithium batteries in 2005. Its core product single crystal ternary anode material turns out to be first-class in the whole industry and lead the trend of technology. Zhenhua E-CHEM won Guizhou's second prize for progress in science and technology in 2012 and in 2017 it received major special funds from Guizhou Science and Technology Department. In the field of power battery, Zhenhua E-CHEM is the main provider of ternary anode material to some first class domestic battery manufacturers like CATL. When it comes to consumption, its shipments account for one third of the anode materials for IPAD globally. Now, many renowned manufacturers put its anode material through a test. In the future, it's possible for the products of Zhenhua E-CHEM to access the supply system of Tesla, a well-known manufacturer of new energy vehicles.
SDIC Venture Capital and SDIC Chuangyi Industry Fund Management invest in Zhenhua by resource synergy and in the way of investment linkage. It not only provides support for the transformation of scientific and technological achievements, accelerates the development of the corporation, contributes to the development of the new energy vehicle industry, but also works as a specific measure to implement the work plans arranged by the Communist Party and the State Council on poverty alleviation and development in this new era, advances regional poverty relief, gives play to government guidance and the leverage of fiscal funds and drives business capitals as well as social capitals to make contributions to the economic development of poverty-stricken areas. This time the cooperation fully demonstrates the synergy effect among SDIC funds and is another successful case of fund synergetic development.
In December 2016, SDIC Venture Capital completed its investment in Eucure (Beijing) Biopharma Co., Ltd (abbreviated as "Eucure Biopharma") with the High-Tech Venture Capital Fund.
Founded in December 2016, Eucure Biopharma is a high-tech enterprise located in Beijing Economic and Technological Development Zone, dedicated to innovative drug research and development. Through the technology platform support from the company's strategic partner, Eucure Biopharma has successfully developed various preclinical antibody products for the R&D of new drugs. At present, Eucure Biopharma's antibody and drug development pipeline is mainly concentrated in the field of cancer treatment. There are already several products that have entered the CMC and are expected to begin to declare clinical trials in 2018. Eucure Biopharma has cooperated with many domestic and foreign pharmaceutical companies in the development of macromolecular drugs including immune checkpoint antibodies, bispecific antibodies, ADC, etc. to find the best treatment for cancer patients.
Through its multi-level and comprehensive value added services after investment, SDIC Venture Capital will assist enterprises in establishing a complete technology and intellectual property system, improving internal management and promoting Eucure Biopharma to become a leader in the research and development of cancer immune drugs.
In December 2017, SDIC Venture Capital accomplished its investment in Chengdu Huajian Pharma Co., Ltd. (hereinafter referred to as HJ Pharma) with National Science and Technology Fund. HJ Pharma focuses on the research and development as well as production of innovative pharmaceutical micromolecule chemicals, which is of great significance to China’s research and development of innovative drugs. With multilevel, all-round value added services after investment, SDIC Venture Capital will help the enterprise establish a complete system of technology and intellectual property and perfect its internal management in hope that HJ Pharma can develop into a leading enterprise in the subdivided industries of biomedicine innovation.
Steered by significant clinical demands and driven by technological innovation, HJ Pharma works on the research and development of innovative drugs with independent intellectual property rights, holding the idea of Chinese wisdom contributing to human health. It’s resolved to become a leading provider of medical blockbusters.
HJ Pharma has established a relatively complete R&D platform which covers drug design, activity evaluation in vitro and in vivo, drug metabolism, synthesis and preparation, quality research, preparations development and pilot magnification. Its product layout is centered on the new generation of tumour micro-environment therapy, the treatment of complex metabolic diseases and other potential significant clinical demands. By now, through independent research and development and introduction, HJ Pharma has formed a development pipeline with great competitiveness and distinct features.
In September, 2016, SDIC Venture Capital completed the investment to Beijing Biocytogen Co., Ltd. (hereinafter referred to as Biocytogen) with High-tech Venture Capital Fund. Biocytogen focuses on gene targeting technologies, products and industrial project applications, fundamentally shoring China's new drugs development. SDIC Venture Capital will assist the enterprise to build a comprehensive technology and IP system, improve inner management and promote Biocytogen to become a great enterprise in innovative biological drugs through multi-layer and all-around post-investment value-added services. After development of almost 8 years, Biocytogen has established a development and service platform of mouse knockout that includes a unique gene targeting vector construction technology with an accurate micro-injection system and high germline transmission efficiency of C57BL/6 mouse embryonic stem cells (ESC). Based on this platform and relying on animal facilities with a combined area of over 10,000 ㎡ at Daxing, Beijing and Haimen, Jiangsu, Biocytogen successfully completed its business transformation from the single service model of preparation of gene engineered animals to the one-stop comprehensive service model of large-scale animal breeding, antibody discovery, and evaluation service of antineoplastic drugs based on Animal Centers. Biocytogen has built a business platform including the development service of genetic editing animal models, large-scale breeding and marketing of animal models, antibody discovery and evaluation service of antineoplastic drugs.
Biocytogen has established a global technical service network which relies on its unique technical platforms, standard operation procedures, strict quality control systems, talented team members, and an efficient executive force. Its customers are from academic institutions such as Harvard University, NIH, Peking University, Tsinghua University, and the Chinese Academy of Sciences. Its clients also include hospitals like Union Hospital, and international companies such as Johnson and Johnson, Roche and other leading pharmaceutical enterprises.
In December 2017, SDIC Venture Capital completed the investment in KBP Biosciences Group (hereinafter referred to as KBP) with its National Science and Technology Fund.
Founded by Dr. Huang Zhenhua, a national expert of "Thousand-Talents Plan", KBP is an international biomedical high-tech enterprise that is devoted to developing original new drugs with independent intellectual property rights to satisfy the huge unmet clinical needs based on innovative research. As a cutting-edge biotech company, KBP specializes in the R&D of innovative medicines for patients with unmet medical needs around the world. Its innovative drug development mindset, independent advantage in pharmaceutical chemistry, and rich clinical development experience and regulatory expertise can help this newcomer find innovative "new chemical entities" (NCEs) for validated targets and bring new hope to the treatment of cardiorenal diseases, infectious diseases, respiratory, inflammatory and autoimmune diseases.
A variety of new drugs under research in KBP has obtained support from national major new drug creation special project. Its leading product under research, KBP-5074, is a mineralocorticoid receptor antagonist, successfully breaking the clinical bottlenecks of existing mineralocorticoid receptor antagonists, is expected to treat cardiovascular diseases. Currently, the Phase II clinical trials of KBP-5074 is underway in the United States. The KBP-7072 is a third-generation aminomethyl tetracycline that is expected to be used in the treatment of multiple drug-resistant bacterial infections. The KBP-7072 has received Fast Track Designations and FDA QIDP certification. It has completed its Phase I trials in the United States and is ready for Phase II. KBP-7026, a CRTH2 antagonist, is expected to treat asthma and COPD.
In December 2017, SDIC Venture Capital accomplished its investment in Hangzhou Lianzhong Medical Science Co., Ltd. (hereinafter referred to as Lianzhong Medical) with National Science and Technology Fund. Lianzhong Medical puts its emphasis on the cross-regional and cross-system platform based on Internet public cloud of medical science, realizing data collection and cloud storage of medical imaging; safe, convenient, and standard transmission of image data; as well as other medical application functions based on cloud storage. Its core product, the medical cloud service platform called “Global Image” has been put into operation in many provinces and cities.
Now, the national health care reform is being further promoted. As a leading company in the field of medical cloud services, Lianzhong Medical plays a significant role in promoting hierarchical diagnosis and treatment; the reform of treating serious diseases without going out of the county and the landing of medical insurance. The Global Image system developed by Lianzhong Medical has solved the problem of resource short in primary hospitals, and has overcome the difficulty of grass-roots patients seeking medical advice. It helps grass-roots patients acquire local high-quality medical resources and services in time and reduces the cost of diagnosis and treatment. Meanwhile, it has established a smooth referral system among upper and lower levels of hospitals, which is of great importance to our society
In December 2017, SDIC Venture Capital accomplished its investment in Beijing Nabai Gen Co., Ltd (hereinafter referred to as NBGen) with Beijing-Tianjin-Hebei Fund. NBGen is an innovator as well as a pioneer in the fields of food safety inspection and animal health in China, providing specialized products and technical services for food safety inspection and prevention, diagnosis and treatment of animal epidemic diseases. As a hi-tech enterprise in Zhongguancun, it has completed the ISO90000 quality system certification.
NBGen was established in 2014 by doctors who had studied abroad and a team with rich experience in product development and marketing. Since the very beginning, it has been providing services for the fields of animal health and biological health with advanced biotechnology, sticking to the management idea of “prevention, diagnosis and treatment”.
In November 2017, SDIC Venture Capital completed the investment in Omni (Suzhou) Pharmaceutical Co., Ltd. (hereinafter referred to as Omni) with its National Science and Technology Fund. Omni is a pharmaceutical company specializing in the R&D and production of respiratory tract drug delivery. Adhering to the tenet of "China manufacture for global sharing", Omni Pharmaceutical Co., Ltd. is committed to breaking the monopoly status of imported pharmaceutical products in the domestic market and providing world-class inhalation preparations. The company was founded in 2011.The R&D center is located in Shanghai Zhangjiang Pharma Valley, and the production base is located in Taicang Biological Industrial Park. Ever since its establishment, Omni has always been supported by internationally renowned investment institutions such as Morningside, Lilly Asia Ventures and KBCP, etc.
Founder Dr. Kai Zhang is a leading expert in the field of respiratory tract drug delivery. He has over 20 years of the R&D and management experience in the field of pharmaceuticals in the United States and China. He has brought several respiratory drug delivery products into the market in the United States. High technical barriers and complex process details make respiratory tract delivery recognized as the industry's high-end preparations. After 6 years of intensive research in the field of respiratory tract administration, Omni has achieved the R&D and production of four mainstream inhalation formulations of powder, aerosol, nasal spray and aerosol, and established a technology platform and production site in line with the international market standard. Among them, the dry powder preparation project has received major national special project support. Furthermore, the company also boasts an independent respiratory device research and development capabilities, which will improve patient compliance into product design. The company's products cover a wide range of respiratory drug delivery in the area, and more than 10 projects under research will enter the clinical research phase this year.
In June, 2017, SDIC Venture Capital contributed with National Science and Technology Fund to lead invest Rongchang Pharmaceuticals,Ltd.,Yantai (hereinafter referred to as RC-Pharma) collaborating with Shenzhen Capital, PAG and Longpan VC. The Major Special Fund will greatly drive RC-Pharma to create the first innovative biological drug for autoimmune diseases and the first antibody-drug conjugate (ADC) antineoplastic in China, gaining new landmark achievements of the industrialization of National Major Scientific and Technological Special Project for “Significant New Drugs Development”.
As an advanced domestic pharmaceutical enterprise covering modern Chinese traditional medicine, innovative biological drug R& D and services, RC-Pharma has undertaken 7 tasks of National Major Scientific and Technological Special Project for “Significant New Drugs Development”. Its technology platform of ADC development so far has the strongest R& D strength in relevant domains in China, whose representative drug, RC-48, has showed the initial effect in Phase I clinical trials, acknowledged as one of the most cutting-edge drugs in China's ADC studies. Meanwhile, RC-Pharma has advanced CDMO service ability in China. It is also the only enterprise that can afford ADC's R& D, manufacture and service, leading the way of the R&D of a number of innovative biological drugs in China.
To lead the investment, SDIC Venture Capital has more ambitions than just promoting RC-Pharma to develop new biological drugs. As the manager of Major Special Fund, through supporting local innovative enterprises in R& D of drugs with a unique development path like RC-Pharma, SDIC Venture Capital hopes to help RC-Pharma perfect its technology platform of new drugs development and modernization of Chinese traditional medicine, constructing an innovative system of R& D of drugs with RC characteristics, ultimately building a first-level pharmaceutical enterprise with international R& D ability and industrial competitiveness.
In December 2017, SDIC Venture Capital completed the investment in Shanghai Zensun Science and Technology Co. Ltd. (hereinafter referred to as Zensun Science and Technology) through National Science and Technology Fund. With this round of investment, the blockbuster of Zensun Science and Technology, rhNRG-1,Neucardin™, can accelerate its process of appearing on China's market and may achieve symbolic achievements of "Significant New Drugs development". rhNRG-1,Neucardin™ is one of the few original innovative drugs which is really developed in China and can access the international market of new drugs. In this round of investment, SDIC Venture Capital intends to provide support for China's world-leading original scientific and technological innovations to reach out to the world and also support the international multi-center clinical trial of the major product of Zensun Science and Technology, so that with its promotion, the rhNRG-1,Neucardin™ can appear on markets both home and abroad as soon as possible.
Zensun Science and Technology is a high-tech biopharmaceutical enterprise driven by the demands of international medical market and based on innovative researches. It focuses on the research and development of original new drugs with independent intellectual property rights. The corporation has two innovative drug research and development platforms focusing on myocardial cell treatment technology and cell energy metabolism treatment technology. It has applied for 186 patents globally and obtained 73 authorizations.
Relying on the myocardial cell treatment technology platform, Zensun Science and Technology has worked on rhNRG-1,Neucardin™ for over a decade, which is the core product used to treat chronic heart failure. This product is literally First-in-Class which not only realizes original innovation but also obtains global patents, rights and interests. It may become a blockbuster. Currently, Zensun Science and Technology has submitted both the ISS and ISE of rhNRG-1,Neucardin™, making clear that the third phase of international multi-center clinical trial of rhNRG-1,Neucardin™ has made big progress.
In addition to this product, the corporation has also discovered that rhNRG-1,Neucardin™ can be used to treat new indications like diastolic heart failure and cerebral stroke. It also developed First-in-Class drugs like rAAV9/cMLCK, which is a gene-based medicine that can be used to treat severe heart failure. Based on the cell energy metabolism treatment platform, the corporation has developed a series of innovative drugs to treat diseases related to senility like functional constipation and Alzheimer disease. The products mentioned above will enter the clinical phase successively in 2018.